High levels of estradiol (E2), present during ovulation and immediately after, diminish a woman's ability to protect against infection, according to a recent study from Spain and Austria. This means that women are more susceptible to fungal infection, such as with Candida Albicans (C albicans), or sexually transmitted diseases, such as HPV or HIV, during ovulation than at any other time during the reproductive cycle.
High levels of estradiol (E2), present during ovulation and immediately after, diminish a woman's ability to protect against infection, according to a recent study from Spain and Austria. This means that women are more susceptible to fungal infection, such as with Candida albicans (C albicans), or sexually transmitted diseases, such as HPV or HIV, during ovulation than at any other time during the reproductive cycle.
To test the hypothesis, researchers set up a model using C albicans and mice. They found that bilaterally ovariectomized mice treated with E2 and injected with a nonlethal dose of C albicans showed a dose-dependent reduction in survival (25% vs 65%) compared with mice not treated with E2. Although most of the control animals survived the infection, only 50% to 70% of the E2-treated mice did so.
Both in vivo and ex vivo models demonstrated that E2-treated mice had a diminished ability to trigger a Th17 immune response to C albicans antigens. The Th17 cellular immune response is essential to a host's protective reaction to fungi; its deregulation may worsen fungal infections significantly. As the authors noted, E2 turned a nonvirulent fungal strain into a disease-causing pathogen.
Relloso M, Aragoneses-Fenoll L, Lasarte S, et al. Estradiol impairs the Th17 immune response against Candida albicans. J Leukoc Biol. 2012;91(1):159-165.
Study: Plant-based diets lower hypertensive disorders of pregnancy risk
March 28th 2024A recent study suggests that adherence to plant-based diets significantly decreases the risk of developing hypertensive disorders of pregnancy, shedding light on dietary interventions for maternal health.
Read More
How genetic variables impact oral contraceptive use and VTE risk
March 27th 2024A comprehensive study delved into the interplay of polygenic and hereditary factors in venous thromboembolism risk among oral contraceptive users, shedding light on potential genetic markers for refined risk assessment and counseling.
Read More